恩格列净通过改善心肌能量学缓解非糖尿病心衰猪模型的不良左室重构
该研究在非糖尿病猪心衰模型中探讨恩格列净的心脏保护机制,发现其可改善不良左室重构和收缩功能,机制与心肌燃料利用从葡萄糖转向酮体、游离脂肪酸和支链氨基酸,从而提高心肌ATP含量和工作效率有关。
要点
- 恩格列净改善非糖尿病猪心衰模型的不良左室重构和收缩功能。
- 恩格列净使心肌燃料利用从葡萄糖转向酮体、游离脂肪酸和支链氨基酸。
- 恩格列净增加心肌ATP含量并提高心肌工作效率。
核心结论
- 恩格列净通过将心肌燃料利用从葡萄糖转向酮体、游离脂肪酸和支链氨基酸,改善心肌能量学,从而缓解非糖尿病猪心衰模型的不良左室重构和收缩功能。
研究设计与样本
- 研究在非糖尿病猪中通过2小时球囊闭塞左前降支近端诱导心衰,共14只动物随机接受恩格列净或安慰剂治疗2个月。
- 采用心脏磁共振成像和三维超声心动图评估,并通过冠状动脉和冠状静脉窦同步采血分析心肌代谢物消耗。
主要发现
- 恩格列净组在2个月时左室质量更低、左室扩张减轻、左室球形度减小,左室收缩功能(射血分数和超声衍生应变)改善,神经激素激活改善。
- 与无心肌梗死动物相比,对照组动物主要通过无氧糖酵解增加心肌葡萄糖消耗,同时减少游离脂肪酸和支链氨基酸利用。
- 恩格列净治疗猪不消耗葡萄糖(心肌葡萄糖摄取和葡萄糖相关酶减少),转而增加酮体、游离脂肪酸和支链氨基酸的摄取及代谢酶表达/活性。
- 恩格列净增加心肌ATP含量并提高心肌工作效率。
临床怎么用
- 该研究提示恩格列净的心脏获益可能不依赖于降糖作用,而是通过改善心肌能量代谢实现。
- 在非糖尿病心衰患者中,恩格列净的应用可能通过燃料利用转换带来心脏保护,但需临床研究验证。
局限性
- 研究为动物模型(非糖尿病猪),样本量较小(n=14),结果不能直接外推至人类。
- 随访时间为2个月,长期效应未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Empagliflozin cardiac benefits in the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial cannot be explained exclusively by its antihyperglycemic activity. OBJECTIVES: The hypothesis was that empagliflozin's cardiac benefits are mediated by switching myocardial fuel metabolism away from glucose toward ketone bodies (KB), which improves myocardial energy production. METHODS: Heart failure was induced in nondiabetic pigs (n = 14) by 2-h balloon occlusion of the proximal left anterior descending artery. Animals were randomized to empagliflozin or placebo for 2 months. Animals were evaluated with cardiac magnetic resonance imaging and 3-dimensional echocardiography. Myocardial metabolite consumption was analyzed by simultaneous blood sampling from coronary artery and coronary sinus. Myocardial samples were obtained for molecular evaluation. Nonmyocardial infarction animals served as comparison. RESULTS: Despite similar initial ischemic myocardial injury in both groups, the empagliflozin group showed amelioration of adverse remodeling at 2 months (lower left ventricular [LV] mass, reduced LV dilatation, less LV sphericity) versus the control group. LV systolic function (LV ejection fraction and echocardiography-derived strains) was improved, as was neurohormonal activation. Compared with nonmyocardial infarction, control animals increased myocardial glucose consumption mainly through anaerobic glycolysis while reducing utilization of free fatty acid (FFA) and branched-chain amino acid (BCAA). Empagliflozin-treated pigs did not consume glucose (reduction in myocardial glucose uptake, and glucose-related enzymes) but instead switched toward utilization of KB, FFA, and BCAA (increased myocardial uptake of these 3 metabolites, and enhanced expression/activity of the enzymes implicated in the metabolism of KB/FFA/BCAA). Empagliflozin increased myocardial ATP content and enhanced myocardial work efficiency. CONCLUSIONS: Empagliflozin ameliorates adverse cardiac remodeling and heart failure in a nondiabetic porcine model. Empagliflozin switches myocardial fuel utilization away from glucose toward KB, FFA, and BCAA, thereby improving myocardial energetics, enhancing LV systolic function, and ameliorating adverse LV remodeling.
引用
- Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol. 2019. PMID: 30999996. doi:10.1016/j.jacc.2019.01.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。